Literature DB >> 25445640

Gamma delta T cell reconstitution is associated with fewer infections and improved event-free survival after hematopoietic stem cell transplantation for pediatric leukemia.

Ross Perko1, Guolian Kang2, Anusha Sunkara2, Wing Leung3, Paul G Thomas4, Mari H Dallas3.   

Abstract

After hematopoietic stem cell transplantation (HSCT), successful engraftment and immune recovery is necessary to protect the patient from relapse and infection. Many studies highlight the importance of conventional αβ T cell recovery after HSCT, but the impact of γδ T cell recovery has not been well described. Here, we investigate the recovery of γδ T cells in 102 pediatric patients with acute leukemia in first clinical remission who underwent allogeneic HSCT at St. Jude Children's Research Hospital from 1996 to 2011. Mean patient age was 10.5 ± 5.9 years (range, .6 to 25.2), and mean survivor follow-up was 2.7 ± 1.8 years (range, .12 to 6.0). Diagnoses included 59% patients with acute lymphoblastic leukemia and 41% patients with acute myelogenous leukemia. Multivariate analysis demonstrated significant impact of the maximum number of CD3(+), CD4(+), and CD8(+) T cells and donor source on the γδ T cell recovery (P < .0001, P < .0001, P < .0001, and P < .004, respectively). Univariate and multivariate models found the number of γδ T cells after HSCT to be associated with infections (P = .026 and P = .02, respectively). We found the probability of infections for patients with an elevated number of γδ T cells was significantly lower compared with patients with low or normal γδ T cells after HSCT (18% versus 54%; P = .025). Bacterial infections were not observed in patients with elevated γδ T cells. Finally, event-free survival was significantly higher in patients with enhanced γδ T cell reconstitution compared with patients with low/normal γδ T cell reconstitution after HSCT (91% versus 55%; P = .04). Thus, γδ T cells may play an important role in immune reconstitution after HSCT.
Copyright © 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Immune reconstitution; Infections; Leukemia; Pediatrics; γδ T cells

Mesh:

Substances:

Year:  2014        PMID: 25445640      PMCID: PMC4288038          DOI: 10.1016/j.bbmt.2014.09.027

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  31 in total

1.  Diversity of T cell repertoire shaped by a single peptide ligand is critically affected by its amino acid residue at a T cell receptor contact.

Authors:  Y Fukui; T Oono; J P Cabaniols; K Nakao; K Hirokawa; A Inayoshi; T Sanui; J Kanellopoulos; E Iwata; M Noda; M Katsuki; P Kourilsky; T Sasazuki
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

2.  Clinical evidence implicating gamma-delta T cells in EBV control following cord blood transplantation.

Authors:  L Farnault; J Gertner-Dardenne; F Gondois-Rey; G Michel; H Chambost; I Hirsch; D Olive
Journal:  Bone Marrow Transplant       Date:  2013-07-08       Impact factor: 5.483

3.  Depletion of T-cell receptor alpha/beta and CD19 positive cells from apheresis products with the CliniMACS device.

Authors:  Michael Schumm; Peter Lang; Wolfgang Bethge; Christoph Faul; Tobias Feuchtinger; Matthias Pfeiffer; Wichard Vogel; Volker Huppert; Rupert Handgretinger
Journal:  Cytotherapy       Date:  2013-10       Impact factor: 5.414

4.  Definition of APC presentation of phosphoantigen (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate to Vgamma2Vdelta 2 TCR.

Authors:  Huiyong Wei; Dan Huang; Xiaomin Lai; Meiling Chen; Weihua Zhong; Richard Wang; Zheng W Chen
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

5.  The analysis of failure times in the presence of competing risks.

Authors:  R L Prentice; J D Kalbfleisch; A V Peterson; N Flournoy; V T Farewell; N E Breslow
Journal:  Biometrics       Date:  1978-12       Impact factor: 2.571

6.  Reconstitution of gammadelta T cell repertoire diversity after human allogeneic hematopoietic cell transplantation and the role of peripheral expansion of mature T cell population in the graft.

Authors:  M Hirokawa; T Horiuchi; Y Kawabata; A Kitabayashi; A B Miura
Journal:  Bone Marrow Transplant       Date:  2000-07       Impact factor: 5.483

Review 7.  Negative depletion of α/β+ T cells and of CD19+ B lymphocytes: a novel frontier to optimize the effect of innate immunity in HLA-mismatched hematopoietic stem cell transplantation.

Authors:  Franco Locatelli; Aurelie Bauquet; Giuseppe Palumbo; Francesca Moretta; Alice Bertaina
Journal:  Immunol Lett       Date:  2013-09-30       Impact factor: 3.685

8.  In vitro expansion of gamma delta T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma.

Authors:  Maka Burjanadzé; Maud Condomines; Thierry Reme; Philippe Quittet; Pascal Latry; Cécile Lugagne; François Romagne; Yanis Morel; Jean François Rossi; Bernard Klein; Zhao Yang Lu
Journal:  Br J Haematol       Date:  2007-10       Impact factor: 6.998

9.  Specificity of monoclonal antibodies against group B streptococcus type II and inhibition of their binding by human secretions.

Authors:  B M Gray; M L Egan; D G Pritchard
Journal:  Pediatr Res       Date:  1988-07       Impact factor: 3.756

Review 10.  Hematopoietic cell transplantation and emerging viral infections.

Authors:  D Chatzidimitriou; E Gavriilaki; I Sakellari; E Diza
Journal:  J Med Virol       Date:  2010-03       Impact factor: 2.327

View more
  41 in total

Review 1.  The role of the thymus in allogeneic bone marrow transplantation and the recovery of the peripheral T-cell compartment.

Authors:  Enrico Velardi; Emmanuel Clave; Franco Locatelli; Antoine Toubert; Lucas C M Arruda; Francesca Benini
Journal:  Semin Immunopathol       Date:  2021-01-08       Impact factor: 9.623

2.  Selective T-cell depletion targeting CD45RA reduces viremia and enhances early T-cell recovery compared with CD3-targeted T-cell depletion.

Authors:  Brandon M Triplett; Brad Muller; Guolian Kang; Ying Li; Shane J Cross; Joseph Moen; Lea Cunningham; William Janssen; Ewelina Mamcarz; David R Shook; Ashok Srinivasan; John Choi; Randall T Hayden; Wing Leung
Journal:  Transpl Infect Dis       Date:  2018-01-16       Impact factor: 2.228

Review 3.  Bohemian T cell receptors: sketching the repertoires of unconventional lymphocytes.

Authors:  Stefan A Schattgen; Paul G Thomas
Journal:  Immunol Rev       Date:  2018-07       Impact factor: 12.988

4.  Impact of γδ T cells on clinical outcome of hematopoietic stem cell transplantation: systematic review and meta-analysis.

Authors:  Lucas C M Arruda; Ahmed Gaballa; Michael Uhlin
Journal:  Blood Adv       Date:  2019-11-12

Review 5.  T cell optimization for graft-versus-leukemia responses.

Authors:  Melinda A Biernacki; Vipul S Sheth; Marie Bleakley
Journal:  JCI Insight       Date:  2020-05-07

6.  Transient Marked Increase of γδ T Cells in WHIM Syndrome After Successful HSCT.

Authors:  Yuta Kawahara; Yukiko Oh; Tamaki Kato; Kiyotaka Zaha; Akira Morimoto
Journal:  J Clin Immunol       Date:  2018-07-04       Impact factor: 8.317

7.  Allogeneic gamma delta T cells as adoptive cellular therapy for hematologic malignancies.

Authors:  Navdeep Jhita; Sunil S Raikar
Journal:  Explor Immunol       Date:  2022-06-07

8.  Deciphering the Contribution of γδ T Cells to Outcomes in Transplantation.

Authors:  Oliver McCallion; Joanna Hester; Fadi Issa
Journal:  Transplantation       Date:  2018-12       Impact factor: 4.939

Review 9.  Immune function in childhood cancer survivors: a Children's Oncology Group review.

Authors:  Gregory M T Guilcher; Linda Rivard; Jennifer T Huang; Nicola A M Wright; Lynette Anderson; Hesham Eissa; Wendy Pelletier; Shanti Ramachandran; Tal Schechter; Ami J Shah; Ken Wong; Eric J Chow
Journal:  Lancet Child Adolesc Health       Date:  2021-02-16

Review 10.  An Unconventional View of T Cell Reconstitution After Allogeneic Hematopoietic Cell Transplantation.

Authors:  Hana Andrlová; Marcel R M van den Brink; Kate A Markey
Journal:  Front Oncol       Date:  2021-02-18       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.